Website stats for Gazyva - gazyva.com
The most common side effects of GAZYVA in CLL were infusion reactions, low white blood cell counts, low platelet counts, low red blood cell counts, fever, cough, nausea, and diarrhea The safety of GAZYVA was evaluated based on patients with relapsed or refractory NHL, including FL (%), small lymphocytic lymphoma (SLL) and marginal zone lymphoma (MZL) (a disease for which GAZYVA is not indica...
gazyva.com was registered 1 decade 3 years ago. It has a alexa rank of #3,282,235 in the world. It is a domain having .com extension. It is estimated worth of $ 480.00 and have a daily income of around $ 2.00. As no active threats were reported recently, gazyva.com is SAFE to browse.
Traffic Report
| Daily Unique Visitors: | 267 |
| Daily Pageviews: | 534 |
Estimated Valuation
| Income Per Day: | $ 2.00 |
| Estimated Worth: | $ 480.00 |
Search Engine Indexes
| Google Indexed Pages: | Not Applicable |
| Yahoo Indexed Pages: | Not Applicable |
| Bing Indexed Pages: | Not Applicable |
Search Engine Backlinks
| Google Backlinks: | Not Applicable |
| Bing Backlinks: | Not Applicable |
| Alexa BackLinks: | Not Applicable |
Safety Information
| Google Safe Browsing: | No Risk Issues |
| Siteadvisor Rating: | Not Applicable |
| WOT Trustworthiness: |
 Very Poor
|
| WOT Privacy: |
Very Poor
|
| WOT Child Safety: |
Very Poor
|
Website Ranks & Scores
| Alexa Rank: | 3,282,235 |
| PageSpeed Score: | 75 ON 100 |
| Domain Authority: |
49 ON 100 
|
| Bounce Rate: | Not Applicable |
| Time On Site: | Not Applicable |
Web Server Information
Hosted IP Address:
72.34.128.116
Hosted Country:
US
Location Latitude:
38.3566Location Longitude:
-121.988Traffic Classification
| Total Traffic: | No Data |
| Direct Traffic: | 0% |
| Referral Traffic: | 0% |
| Search Traffic: | 72.86% |
| Social Traffic: | 0% |
| Mail Traffic: | 0% |
| Display Traffic: | 27.14% |
Search Engine Results For gazyva.com
About GAZYVA® (obinutuzumab) Treatment
Indications. GAZYVA ® (obinutuzumab) is a prescription medicine used in combination with chemotherapy, followed by GAZYVA alone in those who responded, to treat stage II bulky,...
GAZYVA® (obinutuzumab) Premedications | R/R Follicular ...
Closely monitor patients during the entire infusion. Infusion-related reactions within 24 hours of receiving GAZYVA have occurred; a 20 mg dexamethasone or 80 mg...
Gazyva: Side Effects, Dosage & Uses - Drugs.com
Sep 06, 2020 · Gazyva (obinutuzumab) is a cancer medication used to treat chronic lymphocytic leukemia. Includes Gazyva side effects, interactions and indications.
Genentech: Gazyva® (obinutuzumab) - Information for Patients
Genentech: Gazyva® (obinutuzumab) - Information for ...
Genentech’s Gazyva (obinutuzumab), in Combination With ...
Nov 09, 2019 · Genentech’s Gazyva (obinutuzumab), in Combination With Standard of Care, More Than Doubles the Percentage of Lupus Nephritis Patients Achieving …
Gazyva Cancer Medication - Cancer Health
Gazyva is a monoclonal antibody approved for follicular lymphoma and chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, in...
Gazyva (Obinutuzumab) for Leukemia | MyLeukemiaTeam
Overview Gazyva is a prescription drug approved by the Food and Drug Administration (FDA) to treat previously untreated chronic lymphocytic leukemia (CLL).
Roche - Login - GAZYVA
Welcome to the GAZYVA® (obinutuzumab) Website This website is provided by Roche Products Pty Limited and is intended only for patients who have been prescribed GAZYVA®...
Rituxan vs. Gazyva Treatment for Cancer and Leukemia ...
Rituxan (rituximab) and Gazyva (obinutuzumab) are monoclonal antibodies used to treat different kinds of cancer. Gazyva is used in combination with chlorambucil to treat...
Venetoclax (Venclexta®) + Obinutuzumab (Gazyva®) for CLL ...
References. 1) Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions.N Engl J Med 2019;380:2225-2236. 2) Stephens DM....
Gazyva | Roche Australia
Roche Products Pty Limited ABN 70 000 132 865 | Roche Diagnostics Australia Pty Limited ABN 29 003 001 205 | Roche Diabetes Care Australia Pty Limited ABN 69 602 140 278.
Gazyva (obinutuzumab) treatment : My Doctor is... - CLL ...
Hi Winj3, Have you considered trying to get into a combination trial? I ask because for my initial treatment I was offered to be part of an Ibrutinib-Gazyva trial, but my...
Treatment for CLL/SLL and MCL | CALQUENCE® (acalabrutinib)
Learn more about CALQUENCE® (acalabrutinib) and how it treats mantle cell lymphoma and chronic lymphocytic leukemia or small lymphocytic lymphoma in adult patients.
Gazyva: Bula original, extraída manualmente da Anvisa | CR
Gazyva ® deve ser administrado por infusão intravenosa por meio de um acesso venoso exclusivo, em um ambiente onde meios de reanimação estejam imediatamente disponíveis e sob a...
Obinutuzumab (Gazyva) - Pharmacy Times
Background Obinutuzumab (Gazyva), manufactured by Genentech, is a novel anti-CD20 monoclonal antibody FDA approved, in combination with chlorambucil, for the treatment of...
Results Announced for Gazyva vs. Rituxan in CLL Trial - MPR
Nov 08, 2013 · Genentech has announced positive data from a Stage 2, Phase 3 CLL11 study comparing Gazyva (obinutuzumab) to Rituxan (rituximab), both in combination with …
Obinutuzumab (gazyva): Has anyone tried this... - CLL Support
Dr.Sharman practices at the Willamette Valley Cancer Research and Treatment Center in Springfield Oregon. Springfield is a suburb of Eugene. My wife has deep, slender, and...
Venetoclax and Obinutuzumab in Patients with CLL and ...
Among patients with untreated CLL and coexisting conditions, venetoclax-obinutuzumab was associated with longer progression-free survival than chlorambucil-obinutuzumab. (Funded...
Page Resources Breakdown
Homepage Links Analysis
Website Inpage Analysis
| H1 Headings: | Not Applicable | H2 Headings: | 2 |
| H3 Headings: | Not Applicable | H4 Headings: | 5 |
| H5 Headings: | Not Applicable | H6 Headings: | Not Applicable |
| Total IFRAMEs: | Not Applicable | Total Images: | 4 |
| Google Adsense: | Not Applicable | Google Analytics: | Not Applicable |
HTTP Header Analysis
Status-Code: 200
Status: 200 OK
Accept-Ranges: bytes
Content-Encoding: gzip
Content-Type: text/html; charset=UTF-8
Date: Wed, 25 Sep 2019 01:18:16 GMT
Server: Apache
Vary: Accept-Encoding
Content-Length: 14559
Connection: keep-alive
Domain Information
| Domain Registrar: |
SafeNames Ltd.
|
|---|---|
| Registration Date: | 2011-11-10 1 decade 3 years 1 week ago |
| Last Modified: | 2017-12-01 6 years 11 months 2 weeks ago |
Domain Nameserver Information
| Host | IP Address | Country | |
|---|---|---|---|
| hlrns1.roche.com | |
198.21.25.33 | United States |
| ns1.roche.com | |
196.3.50.135 |  Switzerland |
| ns2.roche.com | |
196.3.46.25 | United States |
DNS Record Analysis
| Host | Type | TTL | Extra |
|---|---|---|---|
| gazyva.com | A | 3554 |
IP: 72.34.128.116 |
| gazyva.com | NS | 3600 |
Target: hlrns1.roche.com |
| gazyva.com | NS | 3600 |
Target: ns2.roche.com |
| gazyva.com | NS | 3600 |
Target: ns1.roche.com |
| gazyva.com | SOA | 3600 |
MNAME: ns1.roche.com RNAME: global.hostmaster.roche.com Serial: 2019062501 Refresh: 10800 Retry: 3600 Expire: 604800 |
Top Organic Keyword
| 1. | follicular lymphoma red blood cell count |
| 2. | gazyva |
| 3. | gallium trial |
| 4. | obinutuzumab |
| 5. | obitatuzimab |
Top Paid Keyword
| 1. | follicular lymphoma of small intestine |
| 2. | genentech gazyva |
| 3. | gallium clinical trial |
| 4. | cll14 venclexta obinutuzumab "15 (7)" |
Full WHOIS Lookup
Registry Domain ID:
1686469138_DOMAIN_COM-VRSN
Registrar WHOIS Server:
whois.safenames.net
Registrar URL:
http://www.safenames.net
Updated Date:
2017-12-01T03:35:59Z
Creation Date:
2011-11-10T09:24:17Z
Registry Expiry Date:
2019-11-10T09:24:17Z
Registrar: SafeNames Ltd.
Registrar IANA
ID: 447
Registrar Abuse Contact Email:
[email protected]
Registrar Abuse Contact Phone:
+44.1908200022
Domain Status: clientDeleteProhibited
https://icann.org/epp#clientDeleteProhibited
Domain Status:
clientTransferProhibited
https://icann.org/epp#clientTransferProhibited
Domain Status:
clientUpdateProhibited
https://icann.org/epp#clientUpdateProhibited
Name Server:
HLRNS1.ROCHE.COM
Name Server: NS1.ROCHE.COM
Name Server:
NS2.ROCHE.COM
DNSSEC: unsigned
URL of the ICANN Whois
Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last
update of whois database: 2019-09-25T01:18:50Z
Similarly Ranked Websites
Plymouth Argyle - PAFC
The official website of Plymouth Argyle - PAFC.
3,282,328 
$ 480.00
LoudandProud music with power and feeling ... a universe
hifi stereo amplifiers, receivers, cd, dvd. vinyl, test, audio links, speaker test, archive, webshop, mp3 listening, music, radio, live consert,audio specification, price and...
3,282,365 $ 480.00
Site not found · DreamHost
The owner of this domain has not yet uploaded their website.
3,282,371 $ 480.00